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Introduction
Irosustat, also known as BN83495, 667 COUMATE, or STX64, is an irreversible steroid sulphatase (STS) inhibitor for steroid hormone-dependent cancer therapy, and it is currently under clinical development by the Ipsen Group. STS enzyme is widely distributed throughout the body and regulates the formation of estrone and dehydroepiandrosterone from their corresponding sulphate conjugates. Both compounds can be further converted to estradiol and androstenediol, respectively, which are described to promote tumour growth (Reed et al., 2005; Foster, 2008) . Irosustat exhibits potent STS inhibition both in vitro, showing an IC 50 value of 8 nM in placental microsome preparations (Woo et al., 2000) , and in vivo in MCF-7 xenograft breast cancer model (Foster et al., 2006) , and also causes regression of estrone sulphatestimulated nitrosomethylurea-induced mammary tumours in ovariectomized rats (Purohit et al., 2000) . Moreover, Irosustat was the first STS inhibitor to be tested in phase I clinical trials for the treatment of postmenopausal women with advanced metastatic hormone-dependent breast cancer, showing encouraging results (Stanway et al., 2006; Palmieri et al., 2011) . More recently, STS inhibitors have shown that, in addition to breast cancer therapy may be useful for the treatment of 8 hepatocytes were thawed according to the instructions provided by the supplier, and the viability and cell density were measured by the trypan blue exclusion method. Finally, human hepatocytes were plated in 24-well culture dishes coated with collagen substratum (cell density: 0.4 x 10 6 viable cells/well).
Incubation of 14 C-Irosustat with Liver Microsomes and Determination of Apparent
Intrinsic Clearance. Liver microsomes (1 mg/ml) from Sprague-Dawley rats, Beagle dogs, Cynomolgus monkeys and humans (both sexes separately) were incubated in duplicate with 25 µM 14 C-Irosustat at 37ºC in 50 mM Tris-HCl buffer pH 7.4 containing 5 mM MgCl 2 , and in the presence of a NADPH-generating system consisting of: 4 mM D-glucose 6-phosphate, 2 IU/ml glucose 6-phosphate dehydrogenase and 1 mM β -NADP (0.5 ml final volume). The reactions were started by addition of β -NADP, and were quenched at 0, 30, 60 and 120 min, by addition of one volume of acetonitrile containing 10% acetic acid. Incubation mixtures without microsomes and without β -NADP incubated for 120 min were used as controls. The samples generated were either stored at -80ºC until analysis or directly analysed by HPLC after centrifugation at 20,000 x g at 4°C for 15 min and further dilution with HPLC mobile phase.
For each species and sex, the apparent intrinsic clearance (Cl int,app ) parameter was estimated using the t 1/2 method, where the log-percent of substrate remaining versus time was plotted. For calculation, data from incubations up to 30 min were selected. Since 667-Coumarin is formed by degradation during the incubations, and both Irosustat and 667-Coumarin actually act as a substrate, the percent remaining included both compounds enabling the estimation of the CYP-mediated Cl int,app . The slope of the resulting linear regression (-k) was used to obtain in vitro t 1/2 (in vitro t 1/2 = 0.693 / k). The in vitro t 1/2 was further converted to Cl int,app using the following equation: Cl int,app = [(0.693 / in vitro t 1/2 ) • (ml incubation / mg microsomes) • (45 mg microsomes / g liver) • (X g liver / kg body weight)], where X = 45 for rat, 25 for dog, 30 for monkey, and 20
for human (Bohnert and Gan, 2010) .
Incubation of Unlabelled Irosustat with Hepatocytes. Cultured hepatocytes from male
and female Sprague-Dawley rats, male Beagle dog and woman, were incubated in duplicate with 50 µM unlabelled Irosustat at 37ºC in a humidified atmosphere containing 95% air and 5% CO 2 .
The incubation volume was 0.5 ml and the incubation time period was 3 hours. The incubations were quenched by addition of one volume of acetonitrile containing 3% acetic acid. The samples generated were either stored at -80ºC until analysis or directly analysed by HPLC after centrifugation at 20,000 x g at 4°C for 15 min, and dilution with HPLC mobile phase.
Incubation of Unlabelled Irosustat and 667-Coumarin with Rat Liver Microsomes
and Rat Hepatocytes. Liver microsomes (1 mg/ml) and hepatocytes from female SpragueDawley rats were incubated either with 50 µM Irosustat or with 50 µM 667-Coumarin for 120 minutes (liver microsomes) and 3 hours (hepatocytes), under the same conditions as previously described.
Estimation of the Apparent K M and V max for Irosustat Metabolism in HLM.
Prior assessment of the enzyme kinetics, the linearity of 14 C-labelled Irosustat transformation in HLM was evaluated in a range of increasing microsomal protein concentrations, and incubation time periods. Linear metabolite formation was found up to approximately 1 mg microsomal protein per ml, and up to 40 minutes incubation, respectively (data not shown). These incubation conditions were selected for the enzyme kinetics experiment. The microsomal incubations were conducted with final 14 C-Irosustat concentrations of 0, 5, 10, 25, 50, 80, 110, 150 and 250 µM (n=4 for each concentration, except for 110 and 150 µM, which were n=2). Reactions were
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HPLC Analysis.
14 C-Irosustat and its metabolites were separated by HPLC using a Waters 600 solvent delivery system equipped with a reversed-phase column Sunfire C 18 , 150 x 4.6 mm, 5 µm particle size from Waters (Milford, MA, USA). The mobile phase consisted of 50 mM ammonium formiate pH 5.0 (solvent A) and methanol (solvent B), and the flow rate was 1 ml/min. The initial mobile phase contained 25% solvent B and was maintained at this composition for 2 min. The percentage of solvent B was increased linearly up to 53% over the next 24 min, and further increased to 70% in the following 7 min. The percentage of solvent B was rapidly changed to 100% in 0.1 min, and maintained at this composition for 5 min. Finally, the percentage of solvent B was returned to 25% in the last 7 min. On-line radiochemical detection was performed using a LB508 radioflow detector equipped with 150 µl-solid scintillation cell (YG-150) from Berthold Technologies (Bad Wildbad, Germany). When using non-radiolabeled Irosustat, UV peak detection was made using a Waters 486 variable wavelength
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Mass Spectrometric Characterization. Metabolites in representative incubate samples
were selected for LC-MS characterization. Monitoring of metabolite ions was conducted using a ZQ2000 mass spectrometer (Waters, Milford, MA, USA) over the regions where HPLC peaks were present. The mass spectrometer operated with an electrospray ion source in positive ionization mode. Data were captured by means of full scan mass spectra. The capillary and extractor voltages were set at 3 kV and 3 V, respectively; the RF lens voltage was set at 0.5 V;
the source and desolvation temperatures were set at 120ºC and 250°C, respectively; and the desolvation and cone gas flow rates were 400 and 50 L/h, respectively. Two cone voltages (30V and 60V) were used in order to determine the fragmentation pattern of the compounds. The spectra obtained in chromatograms from incubates with Irosustat or 667-Coumarin were compared to blank samples. Data was acquired by Masslynx 4.0 software (Waters, Mildford, MA, USA).
Phase I Metabolite Isolation. The main phase I metabolites were produced by incubating 50 µM Irosustat or 667-Coumarin with rat liver microsomes (2 mg/ml protein concentration) over 120 minutes as previously described. Incubates were centrifuged and the supernatants diluted with 50 mM ammonium formiate pH 5.0. The metabolites were purified by solid phase extraction (SPE) using SEP-PAK PLUS C-18 cartridges (Waters, Milford, MA, USA). SPE cartridges were activated with acetonitrile and further conditioned with 50 mM ammonium formiate pH 5.0.
Then, diluted supernatants (5 ml) were loaded onto each SPE cartridge, and a washing step was
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Metabolites were separated by HPLC with a Symmetry C 18 column (250 x 4.6 mm, 5 µm, Waters, Milford, MA, USA), and purifed by fraction collection of HPLC elutes. The isolated metabolite fractions were freeze-dried on a Christ Alpha 2-4 Lyophilizer (B.Braun-Biotech, Melsungen, Germany). Freeze-drying procedure was repeated three times. 
NMR Analysis of Isolated Metabolites

Identification of Irosustat Primary Metabolites (containing sulphamoyl group).
Isolated Irosustat primary metabolites were incubated in aqueous buffer at pH 7-8 at 37ºC for 2.5 h in order to induce de-sulphamoylation. The resulting 667-Coumarin derivatives where compared to the NMR identified ones by HPLC co-elution experiments.
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The 14 C-Irosustat metabolites showing a percentage of radioactive peak area higher than 5% were considered as main metabolites. In liver microsomes from the different species under study, the main metabolites were: M7, M8, M13, M14, M16 and 667-Coumarin. They were found in all samples, except for M14 which was not detected in female monkey microsome incubates, appearing only in males. Besides these main metabolites, some minor metabolites accounting for relative percentages below 4.4%, were also detected and showed some differences among species and/or between sexes, although these differences were not considered as relevant.
Taking into account Cl int,app parameters (Table 2) , the highest transformation rate of 14 CIrosustat was observed in monkey liver microsomes (faster in females than in males), followed by rat, dog and human microsomes. The fastest metabolism rate in monkeys was associated with increased production of metabolites M7 and M8 as compared with the other species (see Table   1 ).
This article has not been copyedited and formatted. The final version may differ from this version. The in vitro metabolite profile of 14 C-Irosustat in dog liver microsomes was the closest to the one obtained in HLM both qualitatively and quantitatively, except for metabolite M11 that was detected in human but not in dog microsomes.
Results from control samples without microsomes demonstrated that Irosustat is hydrolyzed to 667-Coumarin under the incubation conditions (at 37ºC and pH 7.4). However, the amount of 667-Coumarin formed in these samples was lower than the amount formed in control samples containing microsomes without ß-NADP (Table 2 ). (Table 4) showed that almost all used inhibitors, except those for CYP1A2 (furafylline) and CYP2C19 (nootkatone and (+)-N-3-benzyl-nirvanol), relevantly decreased the formation of several Irosustat metabolites. Table 5 shows the results obtained in incubations of cDNA-expressed CYP enzymes with Irosustat.
In Vitro Metabolite Profile of Irosustat in Hepatocytes from
Recombinant CYP1A2 and CYP2C19 were able to form most of the Irosustat metabolites produced in HLM incubations. CYP2A6 and FMO enzymes were not able to metabolize Irosustat. Since CYP2B6 was able to form M16 and P-36 but not its respective sulphamoylated precursors M13 and M18, CYP2B6 was additionally incubated with Irosustat for shorter
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Investigation of the
Furafylline alone showed no inhibitory effect either in native or in CYP1A2-fortified HLM, except for a slight inhibition of M14 formation in the latter. The formation of all metabolites was remarkably inhibited by the combination of specific CYP inhibitors in both HLM models.
Approximately the same inhibition percentages were found in Irosustat incubations with native HLM when the mix of inhibitors was used either in presence or in absence of furafylline.
However, in CYP1A2-fortified HLM the inhibition of Irosustat metabolism increased (for almost all metabolites) when furafylline was used together with the mix of CYP-inhibitors.
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As shown in Table 7 , up to nine peaks corresponding to putative glucuronides were produced by the different UGTs. These metabolites were M12 and M2 (already detected in hepatocyte incubations (Fig. 2) ), and the newly detected ones: G1, G2, G3, G4, M4, G7 and G8.
M12 was also formed when 667-Coumarin was incubated directly with all UGTs except for UGT1A4, which, in turn, was the unique UDP-glucuronosyl transferase unable to form any of the glucuronides.
As shown in Table 8 , up to eight peaks corresponding to potential sulphate conjugates were found after incubation of Irosustat phase I metabolites with different human SULTs (1A1*1, 1A1*2, 1A2*1 and 1A3), using the same experimental approach. The sulphate conjugates were named S2, S3, S4, S5, S6 and S7 (new peaks), and were formed in addition to M17 and M3 which had already been detected in hepatocyte incubations (Fig. 2) . M17 formation was also confirmed when 667-Coumarin was incubated directly with all the SULTs.
Sulfotransferases SULT1A1*1, 1A1*2 and 1A2*1, but not SULT1A3, were capable to form M17. SULT1A1*1 was able to produce all the sulphate conjugates identified and also in the largest amounts.
This article has not been copyedited and formatted. The final version may differ from this version. Sulphate metabolites: One sulphate metabolite found in hepatocyte incubates was identified by MS as 667-Coumarin sulphate, and was named as M17.
This article has not been copyedited and formatted. The final version may differ from this version. for 120 minutes and 3 hours, respectively. The metabolite profiles obtained from 667-Coumarin incubations were compared with those obtained with Irosustat. As shown in Fig. 3, M8 , M11, M15, M16, M12, M17 and P-36 were formed directly from 667-Coumarin; conversely, the primary metabolites M7, M9, M13 and M14 were only formed when Irosustat was used as substrate. These results supported the metabolite identification performed by mass spectrometry. The identification of the chemical structure of the mono-oxidized 667-Coumarin derivatives (indeed, the position of the oxidized atoms) was performed by NMR, and the identification of their respective sulphamate-containing derivatives was automatically deduced from the previously described data (see Fig. 4 ). In the case of M8 and M16, their monodimensional 1 H spectra indicated that no changes took place in the aromatic region with respect to 667-Coumarin. The same conclusion was achieved for M15 after interpretation of the
Structure Elucidation of Irosustat Main
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This article has not been copyedited and formatted. The final version may differ from this version. H correlation spectroscopy and total correlation spectroscopy and heteronuclear 1 H-13 C single quantum correlation and multiple bond correlation two-dimension spectra. For all three cases, these spectra indicated that the hydroxyl group was located in the cycloheptane ring.
The position of the hydroxyl group in the cycloheptane ring was determined from the study of the ring atoms in two-dimensional spectra. Thus, metabolites M8, M15 and M16 were hydroxilated at the C10, C12 and C8 positions in the cycloheptane ring of 667-Coumarin molecule, respectively. Obviously, the same hydroxylation sites corresponded to their sulphamatecontaining counterparts M7, M14 and M13. The structures described in Fig. 4 for these metabolites are compatible with the NMR data.
The glucuronidation and the sulphation of 667-Coumarin may basically be formed through its unique hydroxyl group at C3 position, yielding M12 (667-Coumarin 3-O-glucuronide) and M17 (667-Coumarin 3-O-sulphate), respectively (see Fig. 4 ). Metabolites M1 and M2, which were preliminary identified by mass spectrometry as glucuronides (Table 9) , were purified and treated with β -glucuronidase, leading to the formation of M11 and M16, respectively (see Fig. 4 ).
This article has not been copyedited and formatted. The final version may differ from this version. Table 1 The comparison of the microsomal metabolites of Irosustat allowed us to detect metabolic similarities between animal species and humans. These results should be helpful when selecting the non-rodent species for toxicity evaluation. Qualitatively, all phase I human metabolites were formed by dog microsomes except for metabolite M11. Nevertheless, M11 was formed in rats, indicating that no unique human metabolites were formed in liver microsomes, and therefore no safety concerns are anticipated from the in vitro data. Quantitatively, the following rank order was established among species regarding Irosustat Cl int,app (see Table 2 ): monkey>>rat >dog≥humans. As a conclusion, the dog was the species that showed the closest metabolic pattern to humans.
Under in vitro incubation conditions (at 37ºC and pH 7.4), 667-Coumarin was the major degradation product of Irosustat formed by hydrolysis of the sulphamoyl-ester group (Fig. 1) . Desulphamoylation in aqueous solution probably occurs via E1cB elimination reaction, assisted by the extended conjugation present in the coumarin motif (Lloyd et al., 2005) . However, the results of the present work showed how incubations of Irosustat with microsomes in the absence of cofactor produced increased amounts of 667-Coumarin as compared to incubations of Irosustat in buffer alone ( Table 2 ), demonstrating that 667-Coumarin can be also formed by non-NADPHdependent enzymatic hydrolysis. Therefore, 667-Coumarin may be considered as a metabolite and not only a degradation product. Moreover, 667-Coumarin was previously described to be a product resulting after STS inhibition by Irosustat (Woo et al., 2000) . Since the STS enzyme is present in liver microsomes (Kauffman et al, 1998) , STS is a probable candidate for the enzymatic formation of 667-Coumarin.
Once the main metabolites of Irosustat were identified and considering the various phase I and phase II reactions involved, a careful evaluation of the enzymes capable of metabolising
This article has not been copyedited and formatted. The final version may differ from this version. at neutral pH and at 37ºC; and second, by direct incubation of 667-Coumarin with rat microsomes and hepatocytes (Fig. 3) , and with recombinant human CYPs. Due to the structural similarities between Irosustat and 667-Coumarin, it is likely that the same enzymes could be involved in the transformation of both compounds. From the correlation and chemical inhibition tests (Tables 3 and 4) , no relevant differences in phenotyping between the primary metabolites and the respective secondary ones were obtained, except for CYP2E1 which is related to M7 formation but not to M8. In the recombinant CYPs approach, Irosustat and 667-Coumarin were transformed by almost the same enzymes. However, some main differences were obtained: (a)
CYP2A6 was able to metabolize 667-Coumarin but not Irosustat; (b) CYP2C9 was able to metabolize Irosustat but not 667-Coumarin; and (c) CYP2B6 formed M16 from 667-Coumarin but was not able to form M13 from Irosustat. These different capabilities of CYP2A6, CYP2B6, and CYP2C9 to metabolize Irosustat and 667-Coumarin were considered as not relevant given the high number of enzymes involved in the metabolism of both compounds.
This article has not been copyedited and formatted. The final version may differ from this version. Supersomes® showed that this enzyme was able to produce a metabolite profile very similar to the one obtained by pooled HLM. However, the two specific CYP1A2 activities measured in the 16 individual HLM batches, 7-ethoxyresorufin O-dealkylation and phenacetin O-deethylation, did not correlate with the formation of any of the Irosustat metabolites. In addition, the CYP1A2 mechanism-based inhibitor furafylline (1 µM) had no effect on the metabolism of Irosustat in pooled HLM. The inhibition was also assessed using 10-fold increased furafylline and 10-fold reduced Irosustat concentration with similar results (data not shown). Furthermore, the inhibition extent of furafylline on Irosustat metabolism was studied comparatively in incubations with native HLM and CYP1A2-fortified HLM (Table 6 ). As expected, Irosustat metabolism was markedly decreased in both HLM models in the presence of a combination of CYP-specific inhibitors, confirming that Irosustat is metabolised by diverse CYP isoforms. By contrast, furafylline (either alone or in combination with the mix of CYP-inhibitors) showed negligible effect in native HLM, while in CYP1A2-fortified HLM it essentially enhanced the inhibition induced by the other CYP-inhibitors, meaning that several CYPs must be affected at the same time in order to produce any potential metabolic interaction outcome.
Concerning CYP2C19, the S-mephenytoin 4'-hydroxylation activity in 15 individual HLM batches (one was considered as outlier) correlated with the formation of some of the Irosustat metabolites in HLM. In addition, the incubation of Irosustat with recombinant CYP2C19 also produced several Irosustat metabolites. However, the two specific CYP2C19
inhibitors used, nootkatone and (+)-N-3-benzyl-nirvanol (Tassaneeyakul et al, 2000; Suzuki et al, 2002) , did not inhibit the formation of any Irosustat metabolite in the pooled HLM model.
This article has not been copyedited and formatted. The final version may differ from this version. Overall, CYP1A2 and CYP2C19 enzymes were considered as not relevant in Irosustat metabolism when other CYP enzymes are present and active. Although a minor role cannot be completely discarded (i.e. a weak contribution of CYP1A2 in case of overexpression/induction).
From the phenotyping results, we may conclude that, even if co-administered drugs inhibit one of the identified drug-metabolizing enzymes, the pharmacokinetics of Irosustat is unlikely to be noticeably affected due to probable metabolic compensatory mechanisms produced by other CYP isoforms.
When Irosustat phase I metabolites were incubated with different cDNA-expressed UGTs and SULTs, up to nine different glucuronides and eight sulphates were produced, respectively.
Although the actual role of each phase II enzyme was not fully clarified, phase II metabolism is a secondary pathway in Irosustat metabolism and can only occur after phase I transformation of the parent compound, or after formation of 667-Coumarin or any of its hydroxylated metabolites.
Consequently, although highly involved in the overall drug disposition process, phase II enzymes would neither influence Irosustat clearance nor be the target enzymes involved in possible drugdrug interaction processes, unless the biological activity of any of the phase I metabolites was demonstrated.
To summarize, multiple Irosustat metabolic pathways including de-sulphamoylation, primary and secondary metabolism, and phase I and phase II reactions, were involved in the 
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Enzyme
Mean Peak Area G1* G2* G3* G4* M2 M4* G7* G8* M12**
